August 8, 2024

Consolidated Financial Results
for the Three Months Ended June 30, 2024
Terumo Corporation〔IFRS〕
Company name: TERUMO CORPORATION
Listing:
Tokyo Stock Exchange
Securities code:
4543
URL:
https://www.terumo.com/
Representative:
Hikaru Samejima, Chief Executive Officer
Inquiries:
Takashi Miyoshi, General Manager, Investor Relations Dept.
Telephone:+81-3-6742-8550－
Scheduled date to commence dividend payments:
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing:
Yes (for Securities analysts, Institutional investors)(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2024 (from April 1, 2024 to June 30,2024)(1) Consolidated operating results (cumulative)
RevenueThree months
ended
June 30, 2024
June 30, 2023

Operating profit

Profit before tax

Profit attributableto owners of theparentProfit for theperiodTotal
comprehensive
incomeMillions ofyen%Millions ofyen%Millions ofyen%Millions ofyen%Millions ofyen%Millions ofyen%

258,194
215,252

19.9
9.1

44,64029,64450.6(2.6)

45,63529,80453.1
0.5

33,891
22,54950.3
0.7

33,891
22,54950.3
0.7

107,644
107,1720.4(9.0)

Basic earnings
per share
Three months
ended(Percentages indicate year-on-year changes.)

Diluted earnings
per share
Yen

Yen

June 30, 2024

22.82

22.82

June 30, 2023

15.14

15.14

(Note) Adjusted operating profit June 2024: 51,078 million yen June 2023: 34,478 million yen
The Company conducted a two-for-one share split of its common stock effective on April 1, 2024. Basicearnings per share and diluted earnings per share have been calculated on the assumption that the share split
was carried out at the beginning of the previous fiscal year.

(2) Consolidated financial position
Total assets
As ofRatio of equity
attributable to owners of
the parent to total assets

Equity attributable toowners of the parent

Total equity

Millions of yen

Millions of yen

Millions of yen%

June 30, 2024

1,868,956

1,418,461

1,418,461

75.9

March 31, 2024

1,831,402

1,327,090

1,327,090

72.5

2. Cash dividends
Annual dividends per shareFirst quarter-end

Second quarter-end

Third quarter-end

Yen

Yen

Yen

Fiscal year ended
March 31, 2024
Fiscal year ending
March 31, 2025－

Fiscal year-end

Total

Yen

Yen

22.00

－

22.00

44.00

13.00

－

13.00

26.00

－

Fiscal year ending
March 31, 2025
(Guidance)(Note 1) Revision from the dividend guidance, which is published most recently: None
(Note 2) The Company conducted a two-for-one share split of its common stock effective on April 1, 2024. For thesecond quarter and year-end dividends in the year ended March 31, 2024, the amounts of dividends before theshare split are recorded. For the second quarter and year-end dividends in the year ending March 31, 2025
(Guidance), the amounts of dividends are recorded after consideration of the effects of the share split.

3. Consolidated Financial Guidance for the Fiscal Year Ending March 31, 2025 (From April 1, 2024 toMarch 31, 2025)(Percentages indicate year-on-year changes.)
Adjusted operating
profitRevenue
Fiscal year ending
March, 2025

Profit for the year
attributable to ownersof the parent

Operating profit

Basic Earnings per
share

Millions of yen%

Millions of yen%

Millions of yen%

Millions of yen%

Yen

980,000

6.3

185,000

18.0

165,000

17.8

122,000

14.7

82.17

(Note 1) Revision of guidance for the fiscal year ending March 31, 2025, which is published most recently: None
(Note 2) Assumed exchange rate for the fiscal year ending March 31, 2025: USD1=JPY145, EUR1=JPY155

*Notes(1) Significant changes in the scope of consolidation during the period: None
Newly included: － (Company Name: － )Excluded: － (Company Name: － )(2) Changes in accounting policies and changes in accounting estimates(i) Changes in accounting policies required by IFRS: Yes(ii) Changes in accounting policies other than (i): None(iii) Changes in accounting estimates: None
* Please refer to [attached materials], page 13, “2. Condensed Quarterly Consolidated Financial Statements (5)Notes Pertaining to Condensed Quarterly Consolidated Financial Statements (ii) Changes in accounting
policy”.
(3) Number of shares outstanding (common stock)(i) Number of shares outstanding at the end of
the period (including treasury shares)

As of June 30, 2024(ii) Treasury shares at the end of the period

As of June 30, 2024(iii) Average number of shares during theperiod (cumulative quarterly)

Three months ended
June 30, 2024

1,490,697,280 shares As of March 31, 2024 1,490,697,280 shares

5,842,060 shares As of March 31, 2024
1,484,852,049 shares

5,930,404 shares

Three months ended
1,489,281,671 shares
June, 2023

Note: The Company conducted a two-for-one share split of its common stock effective on April 1, 2024.
Number of shares outstanding at the end of the period (including treasury shares), Treasury shares at theend of the period and Average number of shares during the period have been calculated on theassumption that the share split was carried out at the beginning of the previous fiscal year.
* Review of Japanese-language originals of the attached consolidated quarterly financial statements by certified
public accountants or an audit firm: None
* Explanation on appropriate use of financial guidance and other special notes
1. Forward-looking statements, including financial guidance, contained in these disclosure materials are based on
currently available information and assumptions believed to be reasonable by management. This is not apromise or guarantee by the Company that it will achieve these goals. In addition, actual results may differ
significantly due to various factors. For the assumptions that are the premise of the financial guidance and theprecautions for using the financial guidance, refer to [attached materials], page 6, “1. Overview of Financial
Results for the Three Months Ended June 30, 2024 (4) Guidance, including the Consolidated Financial Results
for the Fiscal Year Ending March 31, 2025”.
2. Adjusted operating profit excludes amortization expenses for intangible assets recognized in acquisitions andnon-recurring profit or loss from operating profit. Adjusted operating profit is the basis for segment profit andis disclosed as it is used as a performance indicator for the Group.

Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

 Table of contents of attached materials
1. Overview of Financial Results for the Three Months Ended June 30, 2024 ......................................................... 2(1) Overview of Consolidated Business Results ..................................................................................................... 2(2) Overview of Consolidated Statement of Financial Position .............................................................................. 5(3) Cash flow trends for the three months ended June 30, 2024 ............................................................................. 5(4) Guidance, including the Consolidated Financial Results for the Fiscal Year Ending March 31, 2025 ............. 6
2. Condensed Quarterly Consolidated Financial Statements ..................................................................................... 7(1) Condensed Quarterly Consolidated Statement of Financial Position ................................................................ 7(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated
Statement of Comprehensive Income ............................................................................................................. 9(3) Condensed Quarterly Consolidated Statement of Changes in Equity .............................................................. 11(4) Condensed Quarterly Consolidated Statement of Cash Flows ...................................................................... 12(5) Notes Pertaining to Condensed Quarterly Consolidated Financial Statements ............................................... 13(i) Going concern assumption ............................................................................................................................ 13(ii) Changes in accounting policy ...................................................................................................................... 13(iii) Segment information .................................................................................................................................. 13－ 1 －Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

1. Overview of Financial Results for the Three Months Ended June 30, 2024
(1) Overview of Consolidated Business Results
In the three months of the current fiscal year (from April 1 to June 30, 2024), the Group’s sales trended strongly
amid growing demand for products globally and the effects of foreign exchange rates.
Financial results for the first three months are as follows:(Unit: Millions of yen)
For the threemonths ended
June 30, 2023

For the threemonths ended
June 30, 2024

Growthexcluding
FX impact (%)

Revenue

215,252

258,194

19.9

9.8

Gross profit

109,799

137,569

25.3

11.7

Adjusted operating profit

34,47851,07848.1

23.9

Operating profit

29,64444,64050.6

24.1

Profit before tax

29,80445,635

53.1-

Profit for the period

22,54933,891

50.3-

Profit for the period
attributable to owners of theparent22,54933,891

50.3-

Growth (%)

Revenue by geographic areas for the first three months is as follows:(Unit: Millions of yen)
For the threemonths ended
June 30, 2023

For the threemonths ended
June 30, 2024

Americas74,04595,93929.6

14.8

Europe44,36854,095

21.9

8.3

China

19,95523,04015.5

5.0

Asia and others

29,42832,2999.8

0.1

Overseas total

167,798

205,374

22.4

9.4

Japan

47,454

52,819

11.3

11.3

Total

215,252

258,19419.9

9.8

Geographic areas－ 2 －Growth (%)

Growthexcluding
FX impact (%)

Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

Revenue
Revenue totaled ¥258.2 billion, an increase of 19.9% compared to the same period in the previous fiscal year.
Overseas, revenue increased by 22.4% year on year owing to increased demand in TIS (catheter) division and forblood centers business, along with the effects of foreign exchange rates.
In Japan, revenue increased by 11.3% year on year, amid strong sales of Hospital Care Solutions division andPharmaceutical Solutions division, which pursues alliance business with pharmaceutical companies.
ProfitGross profit totaled ¥137.6 billion, an increase of 25.3% compared to the same period of the previous fiscal year,
because of the higher revenue.
Adjusted operating profit totaled ¥51.1 billion, an increase of 48.1% compared to the same period of the previous
fiscal year, because of the higher gross profit.
Operating profit, profit for the period and profit for the period attributable to owners of the parent respectively
increased amid the increase in gross profit.
Adjusted operating profit is a non-IFRS performance indicator that we disclose. Adjusted operating profit
excludes amortization expenses for intangible assets recognized in acquisitions and non-recurring profit or loss
from operating profit. In addition, adjusted operating profit is consistent with segment profit.
Adjusted operating profit is being used as an indicator for corporate management to grasp earnings performancein each business as a part of our goal to achieve sustainable growth in the mid- to long-term. We believe this isalso effective data for individuals using our financial statements to assess the Group’s earnings.

－ 3 －Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

Revenue results of the reportable segments are as follows:(Unit: Millions of yen)
For the threemonths ended
June 30, 2023

For the threemonths ended
June 30, 2024

Growth (%)

Growthexcluding
FX impact (%)

Revenue

130,584

156,714

20.0

8.1(Overseas)

117,510

143,688

22.3

9.1(Japan)13,07313,025

(0.4)

(0.4)

Revenue

43,68151,757

18.5

15.3(Overseas)

11,794

14,664

24.3

12.5(Japan)31,88737,092

16.3

16.3

Revenue

40,92449,657

21.3

9.2(Overseas)

38,49347,021

22.2

9.2(Japan)

2,430

2,636

8.5

8.5

Segment
Cardiac and
VascularCompany
Medical Care
SolutionsCompany
Blood and Cell
Technologies
Company

Cardiac and Vascular Company
Overseas, revenue increased 22.3% year on year driven by TIS (catheter) division and Neurovascular division, as
all businesses recorded double digit growth. In Japan, sales of Vascular Graft division were strong, but revenue
from TIS (catheter) division declined, resulting in a decrease in revenue of 0.4% year on year. As a result, global
revenue increased by 20.0% compared to the same period of the previous fiscal year to ¥156.7 billion.
Medical Care Solutions Company
In Japan, revenue increased by 16.3% year on year, amid growing demand for Hospital Care Solutions division
and Pharmaceutical Solutions division, along with pricing policy. Overseas, revenue increased 24.3% year on
year owing to higher revenue mainly in the Americas. As a result, global revenue increased by 18.5% comparedto the same period of the previous fiscal year to ¥51.8 billion.
Blood and Cell Technologies Company
Overseas, revenue was up 22.2% year on year as the business for blood centers in the Americas and Europe wasstrong. In Japan, revenue increased 8.5% year on year owing to the increase in revenue of blood center products.
As a result, global revenue increased by 21.3% compared to the same period of the previous fiscal year to ¥49.7
billion.

－ 4 －Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

(2) Overview of Consolidated Statement of Financial Position
Total assets stood at ¥1,869.0 billion, an increase of ¥37.6 billion. This was mainly due to increases in tradeand other receivables and inventories of ¥6.4 billion and ¥13.5 billion, respectively, resulting from foreignexchange rate impacts, and increases in property, plant and equipment of ¥14.6 billion and goodwill andintangible assets of ¥28.8 billion, due to foreign exchange rate impacts and investment in production facilities
and new IT systems. Meanwhile, there was a decrease in other financial assets of ¥19.5 billion due to thesettlement of derivatives associated with the repayment of long-term loans payable, and a decrease in cash andcash equivalents of ¥10.0 billion owing to repayment of long-term loans payable and payment of dividends.
Total liabilities came to ¥450.5 billion, a decrease of ¥53.8 billion. This was mainly due to a decrease in bonds
and borrowings of ¥37.1 billion, resulting from the repayment of long-term loans payable, a decrease in othercurrent liabilities of ¥8.6 billion mainly due to the payment of bonuses, and a decrease of ¥7.0 billion in tradeand other payables due to payments related to equipment.
Total equity was ¥1,418.5 billion, an increase of ¥91.4 billion. This mainly reflects an increase from posting
profit for the period of ¥33.9 billion, as well as the booking of other comprehensive income associated withforeign exchange rate impacts resulted in a ¥73.8 billion increase, which offset a decrease of ¥16.3 billion
from dividends from retained earnings.
(3) Cash flow trends for the three months ended June 30, 2024
(Millions of yen)
For the threemonths ended
June 30, 2023

For the three months
ended
June 30, 2024

ChangeCash flows from operating activities

11,43135,69924,267

Cash flows from investing activities(19,314)(20,736)(1,422)

Cash flows from financing activities(27,524)(33,223)(5,698)Cash and cash equivalents at the end of the period

160,052

194,90934,856

Cash flows from operating activities
Net cash provided by operating activities was ¥35.7 billion. The main factors for this were profit before tax of¥45.6 billion, depreciation and amortization of ¥21.0 billion, income taxes paid of ¥18.2 billion and a decrease intrade and other receivables of ¥5.2 billion.
Cash flows from investing activities
Net cash used in investing activities was ¥20.7 billion. The main factors for this were expenditures of ¥15.3
billion for purchase of property, plant and equipment following capital expenditures for manufacturing facilities,
and expenditures of ¥3.5 billion for purchase of intangible assets following investment in new IT systems.
Cash flows from financing activities
Net cash used in financing activities was ¥33.2 billion. This was mainly due to proceeds from short-termborrowings of ¥20.0 billion, proceeds from long-term borrowings of ¥30.0 billion, proceeds from the issue ofcorporate bonds of ¥69.8 billion, proceeds from settlement of derivative of ¥25.4 billion, expenditures fromrepayment of long-term borrowings of ¥160.3 billion, and payments for dividends of ¥16.2 billion.
In addition to the above, there was a ¥8.3 billion increase from the effect of exchange rate changes on cash andcash equivalents. As a result, the fiscal quarter-end balance of cash and cash equivalents as of the end of the firstquarter stood at ¥194.9 billion, down ¥10.0 billion from the end of the previous fiscal year.

－ 5 －Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

(4) Guidance, including the Consolidated Financial Results for the Fiscal Year Ending March 31, 2025
No changes have been made to the guidance of consolidated financial results announced on May 14, 2024.
Although the operating environment is expected to remain uncertain due to changes in the environment
surrounding the medical device and pharmaceutical industries and trends in foreign exchange rates, to achieve
its targets the Group will focus on the following: development and sales expansion of high value-added
products that contribute to improving the quality and efficiency of medical care, continuous cost improvement,
and effective management of selling, general and administrative expenses.

－ 6 －Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

2. Condensed Quarterly Consolidated Financial Statements(1) Condensed Quarterly Consolidated Statement of Financial Position
As ofMarch 31, 2024

（Unit: Millions of yen）
As of
June 30, 2024

AssetsCurrent assets
Cash and cash equivalents

204,883

194,909

Trade and other receivables

178,710185,061

Other current financial assets

26,158

1,828

Inventories

286,599

300,109

Current tax assets

1,337

1,569

Other current assets

24,42625,292

Total current assets

722,116

708,772

Property, plant and equipment

415,845

430,466

Goodwill and intangible assets
Investments accounted for using
the equity method
Other non-current financial assets

588,225

617,061

2,410

2,458

36,36841,212

Deferred tax assets

19,977

22,945

Other non-current assets

46,45846,040Total non-current assets

1,109,286

1,160,183

1,831,402

1,868,956

Non-current assets

Total assets－ 7 －Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

（Unit: Millions of yen）
As of
June 30, 2024

As ofMarch 31, 2024
Liabilities and Equity
Liabilities
Current liabilities
Trade and other payables

93,77086,793

Bonds and borrowings

156,870

35,000

Other current financial liabilities

7,837

8,153

Current tax liabilities

26,46722,309213

243

Other current liabilities

93,992

85,344

Total current liabilities

379,152

237,843

Bonds and borrowings
Other non-current financial
liabilities
Deferred tax liabilities

74,978

159,786

30,82431,727

3,025

4,997

Retirement benefit liabilities

5,939

6,272

112

120

Other non-current liabilities

10,279

9,747

Total non-current liabilities

125,159

212,651

504,311450,494

Share capital

38,716

38,716

Capital surplus

51,75251,815

Treasury shares(12,436)(12,252)

Retained earnings

954,679

972,156

Other components of equity
Total equity attributable to owners of
the parent
Total equity

294,379

368,025

1,327,090

1,418,461

1,327,090

1,418,461

1,831,402

1,868,956

Provisions

Non-current liabilities

Provisions

Total liabilities
EquityTotal liabilities and equity－ 8 －Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated
Statement of Comprehensive Income(Condensed Quarterly Consolidated Statement of Profit or Loss)（Unit: Millions of yen）
For the three months ended
For the three months ended
June 30, 2023
June 30, 2024
Revenue
215,252
258,194
Cost of sales
105,453
120,624
Gross profit
109,799
137,569
Selling, general and administrative expenses
80,492
92,157
Other income
970
584
Other expenses
632
1,356
Operating profit
29,64444,640Finance income
593
1,522
Finance costs
444
568
Share of profit of investments accounted for
11
41
using the equity method
Profit before tax
29,80445,635
Income tax expenses
7,254
11,744
Profit for the period
22,54933,891Attributable to:
Owners of the parent
Total profit for the period

22,54922,54933,89133,891

Earnings per share
Basic earnings per share (yen)Diluted earnings per share (yen)

15.14
15.14

22.82
22.82

－ 9 －

Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

(Condensed Quarterly Consolidated Statement of Comprehensive Income)

Profit for the period

For the three months ended
June 30, 2023
22,549Other comprehensive income
Items that will not be reclassified to profit orloss
Changes in financial assets measured at fairvalue through other comprehensive income
Total items that will not be reclassified to
profit or loss
Items that are or may be reclassified
subsequently to profit or loss
Exchange differences on translation offoreign operations
Cash flow hedges
Cost of hedging
Total items that are or may be reclassified
subsequently to profit or loss
Total other comprehensive income
for the period
Total comprehensive income for the period（Unit: Millions of yen）
For the three months ended
June 30, 2024
33,891

(64)

1,853

(64)

1,853

84,564

71,845

207

(2)

(84)

56

84,687

71,90084,62273,753

107,172

107,644

107,172

107,644

107,172

107,644

Attributable to:
Owners of the parent
Total comprehensive income for the period(Note) Items in the above statement are net of tax.

－ 10 －

Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

(3) Condensed Quarterly Consolidated Statement of Changes in Equity
For the three months ended June 30, 2023
Equity attributable to owners of the parent
Other
Capital Treasury Retained
components
surplussharesearnings
of equity

Share
capitalBalance as of April 1, 2023

（Unit: Millions of yen）

Total

Total equity

38,71651,759(11,539)874,272

Profit for the period

-

-

-

22,549-22,54922,549Other comprehensive income

-

-

-

-

84,622

84,622

84,622---

22,54984,622

107,172

107,172

Acquisition of treasury shares

-

-

(0)

-

-

(0)

(0)

Disposal of treasury shares

-

(72)

138

-

(65)

0

0

Dividends
Transfer from retained
earnings to capital surplus
Share-based payments
Total transactions with owners of
the parent
Balance as of June 30, 2023

-

-

-

(15,636)- (15,636)(15,636)

-

72

-

(72)

-

-

-

-

63

(0)

-

-

62

62

-

63

136

(15,709)(65) (15,575)(15,575)

38,716

51,822(11,403)881,113242,412 1,202,660

1,202,660

Total comprehensive income

157,855 1,111,063

For the three months ended June 30, 2024

Balance as of April 1, 2024

（Unit: Millions of yen）
Equity attributable to owners of the parent
Other
Capital Treasury Retained
components
surplussharesearnings
of equity

Share
capital1,111,063

Total

Total equity

38,71651,752(12,436)

954,679

Profit for the period

-

-

-

33,891-33,89133,891Other comprehensive income

-

-

-

-

73,75373,75373,753---33,89173,753

107,644

107,644

Acquisition of treasury shares

-

-

(2)

-

-

(2)

(2)

Disposal of treasury shares

-

(81)

188

-

(107)

0

0

Dividends
Transfer from retained
earnings to capital surplus
Share-based payments
Total transactions with owners of
the parent
Balance as of June 30, 2024

-

-

-

(16,332)- (16,332)(16,332)

-

81

-

(81)

-

-

-

-

62

(1)

-

-

61

61

-

62

184

(16,413)(107) (16,273)(16,273)

38,71651,815(12,252)

972,156

368,025 1,418,461

1,418,461

Total comprehensive income－ 11 －

294,379 1,327,090

1,327,090

Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

(4) Condensed Quarterly Consolidated Statement of Cash Flows

Cash flows from operating activities
Profit before tax
Depreciation and amortization
Impairment losses
Share of the (profit)/loss of investments accounted
for using the equity method
Increase/(decrease) in retirement benefit assets or
liabilities
Interest and dividend income
Interest expenses
Foreign exchange (gain)/loss(Gain)/loss on disposal of property, plant andequipment(Increase)/decrease in trade and other receivables(Increase)/decrease in inventories
Increase/(decrease) in trade and other payables
OthersSub-totalInterest and dividend income received
Interest expenses paid
Income taxes paid
Net cash provided by operating activities
Cash flow from investing activities
Payments for purchase of time deposits
Proceeds from withdrawal of time deposits
Payments for purchase of property, plant andequipment
Proceeds from sale of property, plant andequipment
Payments for purchase of intangible assets
Payments for purchase of financial instruments
Payments for acquisition of shares of subsidiaries,
affiliates and other businesses
Net cash used in investing activities－ 12 －For the three months
ended
June 30, 2023
29,804
17,959(Unit: Millions of yen)
For the three months
ended
June 30, 2024-

45,63521,003
1,266

(11)

(41)

689

412

(438)
409
(553)

(764)
563
406

(324)

(40)

1,315
(5,161)(6,358)(9,018)28,312
1,154(470)(17,565)
11,431393
1,991(5,154)(12,187)
53,483998(563)(18,218)
35,699-(214)
0(14,651)(15,262)611

147(4,463)(691)(3,542)(1,765)

(119)

(100)

(19,314)(20,736)

Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

Cash flow from financing activities
Proceeds from short-term borrowings
Proceeds from long-term borrowings
Repayments of long-term borrowings
Proceeds from issue of corporate bonds
Payments for redemption of corporate bonds
Repayments of lease liabilities
Payments for purchase of treasury shares
Payments for dividends
Proceeds from settlement of derivative
Net cash used in financing activities
Effect of exchange rate changes on cash and cash
equivalents
Net increase/(decrease) in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the period

For the three months
ended
June 30, 2023

(Unit: Millions of yen)
For the three months
ended
June 30, 2024(315)
(10,000)(1,786)(0)(15,422)(27,524)

20,00029,969(160,278)

8,137

8,286

(27,269)
187,322160,052(9,973)204,883
194,90969,826(2,004)(2)(16,153)
25,420(33,223)(5) Notes Pertaining to Condensed Quarterly Consolidated Financial Statements(i) Going concern assumption
Not applicable(ii) Changes in accounting policy
The Group has adopted the standard and interpretation below from the first quarter of the fiscal year ending
March 31, 2025.
Standard/Interpretation
IAS 1

Outline of the new standards, interpretations and amendments

Clarification of requirements for classifying liabilities as current or
non-current
Presentation of Financial Statements
Amendments of requirement to disclose information about noncurrent liabilities with covenants

There is no material effect of adopting the standard on the Group’s condensed quarterly consolidated financial
statements for the three months ended June 30, 2024.
(iii) Segment information(1) General information on reportable segments
The reportable segments of the Group represent business units which have available discrete financial
information and are reviewed regularly at the Board of Directors meeting to make decisions about allocationof management resources and assess segment performance.
The Group adopts an in-house company system classified by product groups. The headquarter of each inhouse company plans their own comprehensive domestic and international strategies and conducts their own
business activities.
Therefore, the Group consists of three reportable segments, Cardiac and Vascular Company, Medical Care
Solutions Company, and Blood and Cell Technologies Company, which are organized by the product groups
based on the in-house company system.

－ 13 －

Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

(2) Reportable segment information
Revenue and operating results of the reporting segments of the Group are described below.
For the three months ended June 30, 2023

Reportable Segments

Revenue
Revenue from sales
to externalcustomers
Segment profit(Adjusted
operatingprofit)(Adjustment item)
Amortization of
intangible assets
acquired throughbusiness
combinations
Non-recurring profit orloss (Note 2)(Unit: Millions of yen)Amountrecorded oncondensed
Adjustments
quarterly(Note 1)
consolidated
financialstatements

Cardiac and
VascularCompany

MedicalCare
SolutionsCompany

Blood and
Cell
Technologies
Company

130,584

43,68140,924215,19062215,252

26,883

2,814

5,857

35,554(1,076)34,478(2,224)-(2,529)(4,754)138(4,615)

Total

(218)

Operating profit

29,644

Finance income

593

Finance costs
Share of profit/(loss) ofinvestment accounted
for using the equity
methodProfit before tax

(444)
11
29,804(Note 1) Amounts in “Adjustments” are as follows:(1) ¥62 million adjustment to Revenue from sales to external customers is mainly proceeds fromoutward temporary staffing that is not attributable to reportable segments.
(2) ¥(1,076) million adjustment to Segment profit consists of ¥(722) million for preparation expenses
to comply with Medical Device Regulation in the EU and ¥(416) million for inventories.
(Note 2) ¥(218) million Non-recurring profit or loss is business reorganization expenses.

－ 14 －

Terumo Corporation (4543) Consolidated Financial Results for the Three Months Ended June 30, 2024

For the three months ended June 30, 2024

Reportable Segments

Revenue
Revenue from sales
to externalcustomers
Segment profit(Adjusted
operatingprofit)(Adjustment item)
Amortization of
intangible assets
acquired throughbusiness
combinations
Non-recurring profit orloss(Note 2)(Unit: Millions of yen)Amountrecorded oncondensed
Adjustments
quarterly(Note 1)
consolidated
financialstatements

Cardiac and
VascularCompany

MedicalCare
SolutionsCompany

Blood and
Cell
Technologies
Company

156,71451,75749,657258,12865

258,194

37,157

6,513

6,805

50,476602

51,078(2,588)-(2,867)(5,456)(98)(5,555)

Total

(882)

Operating profit

44,640Finance income

1,522

Finance costs
Share of profit/(loss) ofinvestment accounted
for using the equity
methodProfit before tax

(568)
41
45,635(Note 1) Amounts in “Adjustments” are as follows:(1) ¥65 million adjustment to Revenue from sales to external customers is mainly proceeds fromoutward temporary staffing that is not attributable to reportable segments.
(2) ¥602 million adjustment to Segment profit consists of ¥(524) million for preparation expenses
to comply with Medical Device Regulation in the EU and ¥1,291 million for inventories.
(Note 2) ¥(882) million Non-recurring profit or loss mainly includes ¥(1,099) million for businessreorganization expenses.

－ 15 －